Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Mylan to Cut Thousands of Jobs in Global Restructuring

By Ryan Bushey | December 8, 2016

Mylan submitted a regulatory filing on Wednesday alerting the Securities and Exchange Commission it would implement a restructuring process to cut costs and streamline operations.

Part of this process will include cutting less than 10 percent of its global workforce. The company employs about 35,000 people, which means an estimated 3,500 jobs could be lost.

The generic drug-maker explained in its filing this decision was made, “after a significant number of acquisitions,” according to Reuters. The document didn’t specify details like how much this effort would cost, but the company promised to disclose more details as the plan becomes finalized.

Mylan came under government scrutiny earlier this year over high price hikes for the EpiPen allergy treatments. Heather Bresch, the CEO of the company, was called before Congress in September to testify about these price increases. The price of a two-pack of these injectors went from $100 in 2008 to over $600 in 2016.

Mylan has attempted to make amends with this controversy.

The firm announced in October it would pay over $465 million to the Justice Department to settle allegations it overbilled Medicaid for the EpiPen. Plus, it promised to launch a generic version of the device next year that will sell for $300.

Still, investors didn’t seem thrilled with the news of the restructuring efforts. Mylan’s stock sank over 5 percent in early morning trading, but slightly recovered in the early afternoon only being down 3 percent.


Filed Under: Drug Discovery

 

Related Articles Read More >

Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE